ONE WAY LIVER GENOMICS SL has a total of 21 patent applications. Its first patent ever was published in 2002. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Mexico. Its main competitors in its focus markets measurement and biotechnology are SANKO JIYUNYAKU KK, NINGBO RUI BIO TECH CO LTD and MERCEY THIBAUT.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 8 | |
#2 | WIPO (World Intellectual Property Organization) | 5 | |
#3 | Mexico | 2 | |
#4 | United States | 2 | |
#5 | Argentina | 1 | |
#6 | Australia | 1 | |
#7 | Canada | 1 | |
#8 | Spain | 1 |
# | Industry | |
---|---|---|
#1 | Measurement | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Analysing materials | |
#2 | Measuring microorganism processes | |
#3 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Mato De La Paz Jose Maria | 16 |
#2 | Castro Espido Azucena | 9 |
#3 | Barr Jonathan | 8 |
#4 | Martinez Chantar Maria Luz | 7 |
#5 | Corrales Izquierdo Fernando | 3 |
#6 | Paz Jose Maria Mato De La | 3 |
#7 | Santamaria Martinez Enrique | 3 |
#8 | Galan Cousillas Asier | 2 |
#9 | Elortza Basterrika Felix | 2 |
#10 | Chantar Maria Luz Martinez | 2 |
Publication | Filing date | Title |
---|---|---|
EP2309276A1 | Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile | |
EP2313782A1 | Proteomic fingerprint for the diagnosis of non-alcoholic steatohepatitis (nash) and/or steatosis | |
EP2157431A1 | Method for the diagnosis of NASH using metabolic profiles | |
US2006205023A1 | Sp1 as a marker in diagnosis and prognosis of non-alcoholic steatohepatitis (NASH) and target in drug screening for NASH | |
EP1701166A1 | Phosphorylated SP1 as a marker in diagnosis of non-alcoholic steatohepatitis (nash) and target in drug screening for nash | |
EP1619257A1 | Method for the in vitro diagnosis of non-alcoholic steatohepatitis | |
ES2226549A1 | METHOD FOR THE DIAGNOSIS OF NON-ALCOHOLIC ESTEATOHEPATITIS (NASH) THROUGH THE USE OF MOLECULAR MARKERS. |